ALLO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Allogene Therapeutics's float shares is 156.71 Mil. Allogene Therapeutics's total shares outstanding is 217.26 Mil. Allogene Therapeutics's float percentage of total shares outstanding is 72.13%.
Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Allogene Therapeutics's Insider Ownership is 6.95%.
Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Allogene Therapeutics's Institutional Ownership is 89.87%.
It is the percentage of float shares out of the total shares outstanding.
Allogene Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:
Float Percentage of Total Shares Outstanding | = | Float Shares | / | Total Shares Outstanding |
= | 156.71 | / | 217.26 | |
= | 72.13% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
David D Chang | director, officer: President and CEO | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Deborah M. Messemer | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Earl Martin Douglas | officer: GENERAL COUNSEL | BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067 |
Zachary Roberts | officer: EVP of R&D | C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
Geoffrey M. Parker | officer: CHIEF FINANCIAL OFFICER | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Timothy L. Moore | officer: Chief Technical Officer | C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404 |
Franz B Humer | director | 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013 |
Arie Belldegrun | director, 10 percent owner | UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738 |
Yinlin Jack Chen | officer: SVP, Finance | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Stephen Mayo | director | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Lillian Smith | officer: VP, Corporate Counsel | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Veer Bhavnagri | officer: General Counsel | C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Owen N. Witte | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Rafael Amado | officer: EVP of R&D and CMO | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Alison Moore | officer: Chief Technical Officer | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired • 11-18-2024
By GuruFocus News • 12-09-2024
By Marketwired • 11-19-2024
By GuruFocus News • 11-08-2024
By Marketwired • 11-07-2024
By GuruFocus News • 03-14-2025
By GuruFocus News • 03-13-2025
By GuruFocus News • 02-14-2025
By Marketwired • 10-30-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.